$COO — AVOID 📊 | 6 MONTHS THESIS

$COO — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: MED 🎯 FQ2 FY2026 (ends Apr) | reported Jun 04 | Rev $1.1B | EPS $1.21 vs $1.10 🟢 | Margin -20.8% 💡 The market may be reacting to the headline beat, but the true financial picture—GAAP net loss, unsustainable SG&A spend, zero revenue growth—is far weaker. Consensus estimates likely fail to fully price the risk of derating. 🏢 Business Quality: 3 — 68% gross margin highlights product strength, but operating margin is -20.8% due to bloated SG&A, and the business isn’t scaling (revenue flat YoY)./10 📊 Valuation: rich — non-GAAP P/E of 14.7x is misleading given negative GAAP earnings; EV/Sales of 14.4x is extremely expensive for a company with negative margins... 🔮 Catalyst: Next quarterly earnings report ⚖️ Avoid COO: Headline EPS beat is a low‑quality mask for negative GAAP earnings, a loaded cost structure, and an overpriced valuation with zero growth.

🧭 Conviction: MED